Trial Information

Summary: Combination Rebif and Oral Cladribine Therapy for Multiple Sclerosis

MS patients who are currently taking Rebif are invited to participate in this study if they have had a relapse within the past year. Eligible patients will have either oral cladribine or placebo tablets added to their Rebif treatment. The study duration is 96 weeks and all medication and study related procedures are provided at no cost to the patient.

Patient Inclusion Criteria

• Must have a diagnosis of a relapsing form of Multiple Sclerosis
• Be between 18 and 55 years old
• Have been taking Rebif for at least the last 48 weeks
• Must have had at least one relapse in the past year

Patient Exclusion Criteria

• Not eligible if you have received immunosupressive or cytotoxic agents in the past

If you would like to learn more about participating in this study, please send an e-mail message using the form below.